AU2017211383A1 - Use of histone deacetylase inhibitors for enhancing immunotherapies - Google Patents

Use of histone deacetylase inhibitors for enhancing immunotherapies Download PDF

Info

Publication number
AU2017211383A1
AU2017211383A1 AU2017211383A AU2017211383A AU2017211383A1 AU 2017211383 A1 AU2017211383 A1 AU 2017211383A1 AU 2017211383 A AU2017211383 A AU 2017211383A AU 2017211383 A AU2017211383 A AU 2017211383A AU 2017211383 A1 AU2017211383 A1 AU 2017211383A1
Authority
AU
Australia
Prior art keywords
pct
entinostat
tumor
cells
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017211383A
Other languages
English (en)
Inventor
Roberto PILI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of AU2017211383A1 publication Critical patent/AU2017211383A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2017211383A 2016-01-28 2017-01-27 Use of histone deacetylase inhibitors for enhancing immunotherapies Abandoned AU2017211383A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662288121P 2016-01-28 2016-01-28
US62/288,121 2016-01-28
PCT/US2017/015389 WO2017132536A1 (en) 2016-01-28 2017-01-27 Use of histone deacetylase inhibitors for enhancing immunotherapies

Publications (1)

Publication Number Publication Date
AU2017211383A1 true AU2017211383A1 (en) 2018-08-16

Family

ID=58010402

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017211383A Abandoned AU2017211383A1 (en) 2016-01-28 2017-01-27 Use of histone deacetylase inhibitors for enhancing immunotherapies

Country Status (13)

Country Link
US (1) US10813919B2 (https=)
EP (1) EP3407913A1 (https=)
JP (1) JP2019503386A (https=)
KR (1) KR20180104122A (https=)
CN (1) CN108883179A (https=)
AU (1) AU2017211383A1 (https=)
BR (1) BR112018015291A2 (https=)
CA (1) CA3013047A1 (https=)
IL (1) IL260765A (https=)
MX (1) MX2018009247A (https=)
RU (1) RU2018130831A (https=)
WO (1) WO2017132536A1 (https=)
ZA (1) ZA201805066B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
US12016900B2 (en) 2017-06-04 2024-06-25 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
WO2018225063A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
US12070489B2 (en) 2018-12-12 2024-08-27 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with a cancer therapy in combination with another therapeutic agent
IL264068B2 (en) * 2018-01-05 2023-07-01 Great Novel Therapeutics Biotech & Medicals Corp Aggregate and pharmaceutical preparation containing an hdac inhibitor and an nsaid aggregate together with an immune checkpoint inhibitor for use in a method for removing immunosuppression in the microenvironment of a tumor or stimulating an immune system against cancer cells
CN111836636A (zh) * 2018-01-12 2020-10-27 维拉克塔治疗公司 用于细胞免疫疗法的表观遗传修饰剂
KR20210028339A (ko) * 2019-09-04 2021-03-12 크리스탈지노믹스(주) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
CN112569360A (zh) * 2019-09-30 2021-03-30 中国医学科学院药物研究所 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用
WO2023017525A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
EP4705341A1 (en) * 2023-05-05 2026-03-11 Euro-Celtique S.A. Combinations for treating cancer
WO2024238811A2 (en) * 2023-05-18 2024-11-21 Avstera Therapeutics Corp. Composition comprising hdac inhibitor and immune checkpoint inhibitor and methods for using the same
US12553903B2 (en) 2023-06-01 2026-02-17 Cg Pharmaceuticals, Inc Ivaltinostat combination therapy for treating pancreatic cancer
WO2025155922A1 (en) * 2024-01-19 2025-07-24 The Trustees Of Indiana University Hdac3 inhibitors to treat arrhythmogenic cardiomyopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101523391B1 (ko) 2006-12-27 2015-05-27 에모리 유니버시티 감염 및 종양 치료를 위한 조성물 및 방법
US9987258B2 (en) 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
ES2986548T3 (es) * 2015-03-20 2024-11-11 Syndax Pharmaceuticals Inc Combinación de inhibidor de HDAC y anticuerpo anti-PD-1 para el tratamiento del cáncer, en donde la combinación no comprende 5-azacitidina
US20180250320A1 (en) 2015-08-26 2018-09-06 The Johns Hopkins University Compositions and methods for treating solid tumors
BR112018003238A2 (en) * 2015-09-02 2018-09-25 Syndax Pharmaceuticals, Inc. patient selection for combination therapy

Also Published As

Publication number Publication date
MX2018009247A (es) 2019-03-11
IL260765A (en) 2018-10-31
US20190030011A1 (en) 2019-01-31
WO2017132536A1 (en) 2017-08-03
US10813919B2 (en) 2020-10-27
JP2019503386A (ja) 2019-02-07
CA3013047A1 (en) 2017-08-03
EP3407913A1 (en) 2018-12-05
RU2018130831A (ru) 2020-03-02
RU2018130831A3 (https=) 2020-04-23
BR112018015291A2 (pt) 2018-12-18
KR20180104122A (ko) 2018-09-19
ZA201805066B (en) 2019-05-29
CN108883179A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
US10813919B2 (en) Use of histone deacetylase inhibitors for enhancing immunotherapies
Bauer et al. Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of antiangiogenic therapy
Shen et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models
EP4592391A2 (en) Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
EP2234642B1 (en) Method of increasing immunological effect
WO2020243911A1 (zh) Nad+和/或nad+抑制剂和/或nad+激动剂的用途及其联合制剂
Yan et al. The effect of caloric restriction on the increase in senescence-associated T cells and metabolic disorders in aged mice
US20230172984A1 (en) CLEARANCE OF SENESCENT CELLS BY ACTIVATION OF iNKT CELLS
WO2017144543A1 (en) Combination therapies comprising immuno-oncology agents and belinostat
Ghofrani et al. Nanodepots encapsulating a latency reversing agent and broadly neutralizing antibody enhance natural killer cell cytotoxicity against an in vitro model of latent HIV
US20240366954A1 (en) Compositions, systems, and methods for treating cancer using tumor treating fields and killer cells
WO2014180269A2 (zh) 间充质干细胞在预防或治疗应激反应导致的免疫力下降中的应用
Garcia et al. Clinical and immunomodulatory effects of bevacizumab and low‐dose interleukin‐2 in patients with metastatic renal cell carcinoma: results from a phase II trial
US20200188482A1 (en) Targeting gamma-delta t cells in obesity and cachexia
Foureau et al. Skin tumor responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell expansion in an immunocompetent mouse model
Wagner The Band Aide of the Broken Heart: The Immunomodulatory Properties of Cortical Bone Derived Stem Cells Post Ischemic Injury
Liu Hypoxia Activated Prodrug and Anti-Angiogenic Therapy Cooperate to Treat Pancreatic Cancer But Elicit Immune Suppressive G-Mdsc Infiltration
Hinshaw Hedgehog Signaling Rewires M2 Macrophage and Regulatory T Cell Metabolism Within the Tumor Microenvironment of Breast Cancer
HK40088829B (en) Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
HK40088829A (en) Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
HK40123807A (en) Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
Vanhie et al. Chapter VI–Thesis Aim 3
WO2025217270A1 (en) METHODS OF TREATMENT USING TGFb-RECEPTOR 1 INHIBITION AND LTBR AGONISM
US20210113524A1 (en) Methods of treating myeloproliferative disorders
Marignani Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period